- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04708756
Collabree: An Intervention to Improve the Regularity of Medication Intake
Collabree: A Targeted Behavioral Economics-based Intervention to Improve Medication Adherence in Patients With Hypertension
This a clinical study to improve medication adherence among patients with hypertension in Switzerland. Adult men and women who suffer from high blood pressure and have been prescribed a therapy consisting of at least 4 tablets per day can participate in this study.
The investigators intend to examine whether Collabree, a mobile phone application, is effective in supporting patients with hypertension to more successfully following their therapy plan. The study will also investigate if the use of Collabree can help lower blood pressure.
The study consists of 4 visits that take place during a 90-day adherence promotion program plus a 90-day follow-up period. There is also a screening visit before the study to determine whether the participants qualify for the study. The visits are carried out at the University Hospital Basel. Each visit lasts about 1-2 hours. During the visits, blood pressure is measured in the clinic and also through 24-hour ambulatory blood pressure monitoring (ABPM). Participants will also fill out questionnaires.
Participants are randomly assigned to one of 3 groups in a ratio of 1: 1: 1. Two of these groups will receive the Collabree mobile phone application. All participants will receive a box for storing their antihypertensive medication. This box serves as a system for measuring medication intake as it records the time the box is opened and closed. Standard care will given to all participants.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anjali Raja Beharele, PhD
- Phone Number: +41 (0)78 973 7756
- Email: anjali.rajabeharelle@collabree.com
Study Contact Backup
- Name: Pascal Kurz
- Phone Number: +41 (0)79 963 51 52
- Email: pascal.kurz@collabree.com
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel
-
Contact:
- Thilo Burkard, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent as documented by signature
- Over 18 years of age at date of randomization
- Primary or secondary arterial hypertension
- Patient in an outpatient clinical setting
- Prescribed a therapy consisting of 4 or more tablets taken per day
- Stable medication regime that patient has been taking for at least 4 weeks
- Participant administers their own medications
- Participant owns a smartphone with a data plan or constant internet access during the study visits and at home to use the application
- Minimal required smartphone operating system is iOS 12 and Android 8 (Oreo)
- Adequate communication in German or Swiss-German (all study documentation will only be set to the German language).
Exclusion Criteria:
- Cognitive impairment that limits ability to understand and complete questionnaires
- Ongoing evaluation for secondary forms of hypertension
- 3. Changes in the participant's medication treatment plan after the baseline visit during the intervention period, unless due to a diagnosis of symptomatic hypotension (in-clinic blood pressure below 110/60 mmHg and symptoms of orthostasis or dizziness) or stage 2 hypertension (in-clinic blood pressure > 160/100 mmHg); after the endpoint (day 90) visit, a change in the treatment plan will be permitted
- Uncontrolled hypertension (in-clinic blood pressure > 180/110 mmHg)
- Inability to operate a mobile phone and the Collabree application
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
- Pregnancy or intention to become pregnant in next 6 months
- Enrollment of the Sponsor or Investigator, their family members, employees and other dependent persons
- Participation in another clinical trial
- Physician-estimated life expectancy of less than 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group A
Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
|
Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application.
Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
Patients will receive standard care.
|
Experimental: Intervention Group B
Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
|
Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application.
Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
Patients will receive standard care.
|
No Intervention: Control Group
Patients will not receive the Collabree application and will continue to receive standard care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication adherence
Time Frame: 90 days
|
Difference between intervention Group A and the control group in mean medication adherence at endpoint (i.e. the endpoint visit at 90 days) as measured by medication events.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication adherence (3 group comparison)
Time Frame: 90 days
|
Mean change from baseline in medication adherence (monitored by medication events) at endpoint for the intervention Group A vs. intervention Group B relative to the control group.
|
90 days
|
Self-reported medication adherence
Time Frame: 90 days
|
Mean change from baseline in in-app medication adherence (defined as the number of medications self-reported as "taken" during the intervention period of 90 days divided by the number of prescribed medications listed in the in-app medication plan in that same time period) at endpoint for the intervention Group A vs. intervention Group B relative to the control group.
|
90 days
|
Self-assessed medication adherence
Time Frame: 90 days
|
Mean change from baseline in the score on the Hill-Bone Scale (German version) questionnaire on medication adherence for the intervention Group A vs. intervention Group B relative to the control group at endpoint.
|
90 days
|
Blood pressure
Time Frame: 180 days
|
Linear change in systolic and diastolic blood pressure (24h ABPM and in-clinic blood pressure measurement) across time from baseline to follow-up as assessed with a linear mixed regression model.
This linear change will then be compared for the intervention Group A and intervention Group B relative to the control group.
|
180 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thilo Burkard, MD, ISHF, University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COLLABREE-S
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Collabree Mobile Phone Application Medication Adherence Booster
-
Anjali Raja BeharelleMediService AGEnrolling by invitationHypertension | Medication AdherenceSwitzerland
-
University Hospitals Cleveland Medical CenterCompleted
-
Environment and Health Group, Inc.Completed
-
MelanomaPRO, RussiaPrivolzhsky Research Medical UniversityRecruitingNevus | Nevus, Pigmented | Melanoma (Skin) | Basal Cell Carcinoma | Squamous Cell Carcinoma | Bowen's Disease | Nevus, Spitz | Melanoma in Situ | Nevus Halo | Spot PigmentedRussian Federation
-
Northwestern UniversityNational Institute of Mental Health (NIMH)WithdrawnDepressive Symptoms | Anxiety GeneralizedUnited States
-
General Health Council, MexicoEli Lilly and Company; Instituto de Seguridad y Servicios Sociales de los Trabajadores...RecruitingDiabetes Mellitus, Type 2Mexico
-
Chulalongkorn UniversityThai Red Cross AIDS Research Centre; International AIDS SocietyCompletedHIV Prevention | Adherence, Medication | Adolescent Behavior | Mobile Health | Sexual HealthThailand
-
Mbarara University of Science and TechnologyCompletedmHealth | Maternal Health | MultimediaUganda
-
University of MichiganBlue Cross Blue Shield of Michigan FoundationCompletedDiabetes Mellitus | Prediabetic StateUnited States
-
Amit ArjyalBagmati Rural Municipality, Lalitpur, Nepal; Konjyosom Rural Municipality,... and other collaboratorsNot yet recruitingMaternal Health | Infant Health | Severe Maternal Morbidity | Institutional Delivery | Birth Preparedness and Complication Readiness | Neonatal Adverse OutcomeNepal